Led by our faculty team of 25 physicians and scientists, our patients benefit from a team approach that includes our colleagues in radiology, surgery, radiation therapy, hematopathology, and stem cell transplantation, as well as clinical pharmacists, research and clinical nurses, social workers, and dietitians.
Please visit our list of ongoing clinical trials. By participating in these trials, patients have access to the best of what is coming out of the world’s cancer laboratories, in a holistic approach that matches the appropriate treatment to each individual patient’s needs. In addition to testing new drugs and therapies, our clinical trials investigate combinations of standard drugs given in novel ways, and treatments designed to reduce toxicities for patients. Currently, we are studying several novel therapies with unique mechanisms of actions, including small molecules, monoclonal antibodies, and immunotoxins.
Our laboratory’s translational research program, is dedicated to turning the discoveries of basic science, from fields such as molecular science and genetics, into effective treatments for patients. We are leaders in the field of cancer immunotherapy and the development of tumor vaccines and new antibodies, working to activate the human body's own immune system to fight cancer. Other areas of research include designing novel therapies based on molecular pathways and identifying predictive biomarkers in patients to design personalized, targeted therapies.
Please feel free to contact our department and physicians for additional information about lymphoma or myeloma treatments and research at UT MD Anderson Cancer Center.
Cancer Moon Shots
MD Anderson's Moon Shot® Initiative is an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. B-Cell lymphoma and high-risk multiple myeloma are the subject of two Moon Shots®.